| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 12, 2026 | LQDA Liquidia Corporation | Kaseta Michael54 | CFO And COO | Sell | 18,938 | $28.48 | $539,354.24 | -5.3% | - | - | |
| Oct 9, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 9,500 | $544.94 | $5,176,935.89 | -2.8% | - | - | |
| Oct 9, 2026 | ELTP Elite Pharmaceuticals, Inc. | Dash Barry H | Director | Buy | 100,000 | $0.26 | $25,980.00 | +3.1% | - | - | |
| Oct 8, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 9,500 | $534.31 | $5,075,918.83 | -2.8% | - | - | |
| Oct 8, 2026 | PCRX Pacira Biosciences, Inc. | Riker Lauren76 | Senior Vice President, Finance | Sell | 6,000 | $36.32 | $217,920.00 | -8.8% | - | - | |
| Oct 8, 2026 | INM Inmed Pharmaceuticals Inc. | Adar1 Capital Management, LLC78 | 10% Owner | Buy | 10,903 | $1.33 | $14,484.27 | +1.2% | - | - | |
| Oct 7, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 9,500 | $548.95 | $5,215,015.15 | -2.8% | - | - | |
| Oct 7, 2026 | EBS Emergent Biosolutions Inc. | Degolyer Donald W54 | Director | Sell | 17,800 | $7.09 | $126,202.00 | -13.7% | - | - | |
| Oct 6, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 9,500 | $538.67 | $5,117,411.92 | -2.8% | - | - | |
| Oct 6, 2026 | ETON Eton Pharmaceuticals, Inc. | Krempa David | Chief Business Officer | Sell | 4,166 | $55.07 | $229,406.21 | -8.8% | - | - | |
| Oct 5, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 9,500 | $541.64 | $5,145,537.07 | -2.8% | - | - | |
| Oct 5, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Milne George M Jr59 | Director | Sell | 30,000 | $27.70 | $830,904.00 | -3.7% | - | - | |
| Oct 5, 2026 | LQDA Liquidia Corporation | Bloch Stephen M | Director | Sell | 235,477 | $27.13 | $6,387,596.20 | -100% | - | - | |
| Oct 5, 2026 | INM Inmed Pharmaceuticals Inc. | Adar1 Capital Management, LLC78 | 10% Owner | Buy | 42,920 | $1.33 | $57,080.31 | +4.8% | - | - | |
| Oct 2, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 9,500 | $549.37 | $5,219,014.76 | -2.8% | - | - | |
| Oct 2, 2026 | ALKS Alkermes Plc | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2,034 | $41.03 | $83,455.02 | -0.9% | - | - | |
| Oct 1, 2026 | RMTI Rockwell Medical, Inc. | Strobeck Mark62 | President And CEO | Sell | 1,000 | $8.42 | $8,420.00 | -1.6% | - | - | |
| Oct 1, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 9,500 | $576.47 | $5,476,462.44 | -2.8% | - | - | |
| Oct 1, 2026 | UTHR United Therapeutics Corporation | Mahon Paul A46 | EVP &General Counsel | Sell | 8,300 | $564.95 | $4,689,050.65 | -15.5% | - | - | |
| Oct 1, 2026 | EBS Emergent Biosolutions Inc. | Williams Paul Anthony | SVP, Products Business | Sell | 3,000 | $6.53 | $19,590.00 | -1.9% | - | - | |
| Oct 1, 2026 | HIMS Hims & Hers Health, Inc. | Okupe Oluyemi56 | Chief Financial Officer | Sell | 2,000 | $29.70 | $59,400.00 | -0.8% | - | - | |
| Sep 30, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 1,920 | $550.22 | $1,056,425.10 | -0.6% | - | - | |
| Sep 30, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 7,580 | $517.97 | $3,926,177.11 | -2.3% | - | - | |
| Sep 30, 2026 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 3,461 | $29.17 | $100,957.37 | -1.1% | - | - | |
| Sep 29, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 9,500 | $477.42 | $4,535,479.91 | -2.8% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.